Physician profile
Vanja Cuk
NPI 1215022074
$2,836.94
in general payments reported to CMS, 2019-2025
31 companies · $51.34 in 2025
The $51.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $22.02 · 2021: $11.61 · 2022: $304 · 2023: $881 · 2025: $51.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.72 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $574.47 | 2019-2023 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $351.82 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $258.53 | 2019-2023 | |
| Pfizer INC. | $193.85 | 2019-2023 | |
| Lilly USA, LLC | $173.85 | 2019-2023 | Trulicity, Mounjaro |
| Janssen Pharmaceuticals, INC | $142.40 | 2019-2023 | Spravato |
| Merck Sharp & Dohme LLC | $138.64 | 2019-2022 | |
| Amgen INC. | $114.10 | 2019-2023 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $102.90 | 2019-2023 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $92.81 | 2023 | |
| Amarin Pharma, INC. | $82.16 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.50 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $55.71 | 2022 | |
| Abbvie INC. | $49.88 | 2023 | Ubrelvy |
| Allergan, INC. | $47.95 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $44.44 | 2023-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $41.07 | 2022 | |
| Dexcom, INC. | $39.61 | 2023 | Dexcom G6 Transmitter |
| Zyla Life Sciences, INC. | $36.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.95 | 2022-2023 | |
| Astellas Pharma US INC | $26.42 | 2019-2023 | Myrbetriq |
| Edwards Lifesciences Corporation | $24.90 | 2025 | Sapien 3 Ultra Resilia |
| Halozyme INC | $21.20 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2019 | |
| Genentech USA, INC. | $16.15 | 2019 | |
| Antares Pharma, INC. | $15.86 | 2023 | Tlando, Xyosted, Nocdurna |
| Idorsia Pharmaceuticals US INC | $14.63 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.94 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanja Cuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.